Non-Invasive Screening for Fetal Aneuploidy

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.

Inclusion Criteria:

• Subject is willing to provide written informed consent
• Pregnant female with singleton gestation 18 years of age or older
• Subject agrees to provide a 20 to 30 mL venous blood sample
• Subject is one of the following: A) currently scheduled to undergo an amniocentesis and/or CVS procedure, OR B) currently in the first trimester of pregnancy and planning to undergo an amniocentesis in the second trimester
• Subject will receive results of a genetic analysis that includes evaluation of the fetus for aneuploidy

Exclusion Criteria:

• Subject lacks the capacity to provide informed consent
• Twins, triplets or other multiple gestation